Advertisement

Focal Adhesion Kinase (FAK) Overexpression and Phosphorylation in Oral Squamous Cell Carcinoma and their Clinicopathological Significance

  • Aki Kato
  • Koroku KatoEmail author
  • Hiroki Miyazawa
  • Hisano Kobayashi
  • Natsuyo Noguchi
  • Shuichi Kawashiri
Original Article
  • 112 Downloads

Abstract

Focal adhesion kinase (FAK) is involved in progression of various cancers, and FAK overexpression has been associated with cancer invasion and metastasis. However, the involvement of FAK expression in the clinicopathological malignancy of oral squamous cell carcinoma (OSCC) remains unknown. In addition, there is no consensus regarding the role of p16 expression in OSCC. In this study, the immunohistochemically measured expression of FAK, phosphorylated FAK (FAKpY397) and p16 expressions and their associations with clinicopathological features and 5-year survival rates were examined in surgical samples from 70 patients with primary OSCC. FAK and FAKpY397 were expressed at high levels in 42 cases (60.0%) and 34 cases (48.6%), respectively, and 9 cases (12.9%) were positive for p16. FAK expression was significantly correlated with local recurrence, subsequent metastasis, and the mode of invasion. FAKpY397 expression was significantly correlated with both N classification and the mode of invasion. p16 expression was significantly correlated with clinical stage only. Patients having high expression of FAK, FAKpY397, or both showed significantly worse prognosis, but p16 expression showed no significant relation to prognosis. The results suggested that overexpression and phosphorylation of FAK in OSCC may affect cancer progression, such as local invasion and lymph node metastasis, and thereby contribute to life prognosis.

Keywords

Focal adhesion kinase FAK FAKpY397 p16 Oral squamous cell carcinoma Prognosis 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors have no conflict of interest to declare.

References

  1. 1.
    Simard EP, Torre LA, Jemal A (2014) International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol 50:387–403CrossRefGoogle Scholar
  2. 2.
    Schaller MD (2010) Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci 123:1007–1013CrossRefPubMedGoogle Scholar
  3. 3.
    McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC (2005) The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5:505–515CrossRefPubMedGoogle Scholar
  4. 4.
    Lee BY, Timpson P, Horvath LG, Daly RJ (2015) FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther 146:132–149CrossRefPubMedGoogle Scholar
  5. 5.
    Owens LV, Xu L, Dent GA, Yang X, Sturge GC, Craven RJ, Cance WG (1996) Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol 3:100–105CrossRefPubMedGoogle Scholar
  6. 6.
    Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chevalier S (1996) Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer 68:164–171CrossRefPubMedGoogle Scholar
  7. 7.
    McCormack SJ, Brazinski SE, Moore JL Jr, Werness BA, Goldstein DJ (1997) Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene 15:265–274CrossRefPubMedGoogle Scholar
  8. 8.
    Judson PL, He X, Cance WG, Van Le L (1999) Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer 86:1551–1556CrossRefPubMedGoogle Scholar
  9. 9.
    Lark AL, Livasy CA, Calvo B, Caskey L, Moore DT, Yang X, Cance WG (2003) Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer Res 9:215–222PubMedGoogle Scholar
  10. 10.
    Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu ET, Cance WG (1995) Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 55:2752–2755PubMedGoogle Scholar
  11. 11.
    Recher C, Ysebaert L, Beyne-Rauzy O, Mansat-De Mas V, Ruidavets JB, Cariven P, Demur C, Payrastre B, Laurent G, Racaud-Sultan C (2004) Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res 64:3191–3197CrossRefPubMedGoogle Scholar
  12. 12.
    Schlaepfer DD, Mitra SK, Ilic D (2004) Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692:77–102CrossRefPubMedGoogle Scholar
  13. 13.
    Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Allen CT, Lewis JS Jr, El-Mofty SK, Haughey BH, Nussenbaum B (2010) Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 120:1756–1772CrossRefPubMedGoogle Scholar
  15. 15.
    Marur S, D'Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781–789CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Wang MB, Liu IY, Gornbein JA, Nguyen CT (2015) HPV-positive oropharyngeal carcinoma: a systematic review of treatment and prognosis. Otolaryngol Head Neck Surg 153:758–769CrossRefPubMedGoogle Scholar
  17. 17.
    In (2009) International Union against Cancer, LH Sobin, MK Gospodrowicz, CH Wittekind (eds.). TNM Classification of Malignant Tumours. 7th Ed. Wiley-Liss, New York, NYGoogle Scholar
  18. 18.
    Yamamoto E, Kohama G, Sunakawa H, Iwai M, Hiratsuka H (1983) Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer 51:2175–2180CrossRefPubMedGoogle Scholar
  19. 19.
    Theocharis S, Klijanienko J, Giaginis C, Alexandrou P, Patsouris E, Sastre-Garau X (2012) FAK and Src expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Cancer Res Clin Oncol 138:1369–1377CrossRefPubMedGoogle Scholar
  20. 20.
    Heiduschka G, Grah A, Oberndorfer F, Kadletz L, Altorjai G, Kornek G, Wrba F, Thurnher D, Selzer E (2015) Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. Strahlenther Onkol 191:209–216CrossRefPubMedGoogle Scholar
  21. 21.
    Yamamoto E (1994) Role of chemotherapy for oral cancer from the viewpoint of mode of invasion. Asian J Oral Maxillofac Surg 6:113–121Google Scholar
  22. 22.
    Kurokawa H, Yamashita Y, Takeda S, Zhang M, Fukuyama H, Takahashi T (2002) Risk factors for late cervical lymph node metastases in patients with stage I or II carcinoma of the tongue. Head Neck 24:731–736CrossRefPubMedGoogle Scholar
  23. 23.
    Pereira CH, Morais MO, Martins AF, Soares MQ, Alencar Rde C, Batista AC, Leles CR, Mendonça EF (2016) Expression of adhesion proteins (E-cadherin and β-catenin) and cell proliferation (Ki-67) at the invasive tumor front in conventional oral squamous cell and basaloid squamous cell carcinomas. Arch Oral Biol 61:8–15CrossRefPubMedGoogle Scholar
  24. 24.
    Sen S, Carnelio S (2016) Expression of epithelial cell adhesion molecule (EpCAM) in oral squamous cell carcinoma. Histopathology 68:897–904CrossRefPubMedGoogle Scholar
  25. 25.
    Richardson A, Parsons T (1996) A mechanism for regulation of the adhesion-associated proteintyrosine kinase pp125FAK. Nature 380:538–540CrossRefPubMedGoogle Scholar
  26. 26.
    Webb DJ, Donais K, Whitmore LA, Thomas SM, Turner CE, Parsons JT, Horwitz AF (2004) FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 6:154–161CrossRefPubMedGoogle Scholar
  27. 27.
    Avizienyte E, Wyke AW, Jones RJ, McLean GW, Westhoff MA, Brunton VG, Frame MC (2002) Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol 4:632–638CrossRefPubMedGoogle Scholar
  28. 28.
    Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ, Sheppard D, Cheresh DA (2002) Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol 157:149–160CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Aronsohn MS, Brown HM, Hauptman G, Kornberg LJ (2003) Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx. Laryngoscope 113:1944–1948CrossRefPubMedGoogle Scholar
  30. 30.
    Moon HS, Park WI, Choi EA, Chung HW, Kim SC (2003) The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas. Int J Gynecol Cancer 13:640–646CrossRefPubMedGoogle Scholar
  31. 31.
    Brunton VG, Avizienyte E, Fincham VJ, Serrels B, Metcalf CA 3rd, Sawyer TK, Frame MC (2005) Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. Cancer Res 65:1335–1342CrossRefPubMedGoogle Scholar
  32. 32.
    Kornberg LJ (1998) Focal adhesion kinase expression in oral cancers 20:634–9Google Scholar
  33. 33.
    Kornberg LJ (1998) Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Head Neck 20:745–752CrossRefPubMedGoogle Scholar
  34. 34.
    Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R (2005) Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer 113:372–378CrossRefPubMedGoogle Scholar
  35. 35.
    Chiu YW, Liou LY, Chen PT, Huang CM, Luo FJ, Hsu YK, Yuan TC (2016) Tyrosine 397 phosphorylation is critical for FAK-promoted Rac1 activation and invasive properties in oral squamous cell carcinoma cells. Lab Investig 96:296–306CrossRefPubMedGoogle Scholar
  36. 36.
    Han X, Xue L, Zhou L, Gong L, Zhu S, Yao L, Wang S, Lan M, Li Y, Zhang W (2013) The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma. Exp Mol Pathol 95:270–275CrossRefPubMedGoogle Scholar
  37. 37.
    Aust S, Auer K, Bachmayr-Heyda A, Denkert C, Sehouli J, Braicu I, Mahner S, Lambrechts S, Vergote I, Grimm C, Horvat R, Castillo-Tong DC, Zeillinger R, Pils D (2014) Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium. Mol Cancer 13:67CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Lai IR, Chu PY, Lin HS, Liou JY, Jan YJ, Lee JC, Shen TL (2010) Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance. Am J Pathol 177:1629–1637CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Albasri A, Fadhil W, Scholefield JH, Durrant LG, Ilyas M (2014) Nuclear expression of phosphorylated focal adhesion kinase is associated with poor prognosis in human colorectal cancer. Anticancer Res 34:3969–3974PubMedGoogle Scholar
  40. 40.
    Ding L, Sun X, You Y, Liu N, Fu Z (2010) Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in human gliomas is associated with unfavorable overall survival. Transl Res 156:45–52CrossRefPubMedGoogle Scholar
  41. 41.
    Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE (2003) RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun 311:786–792CrossRefPubMedGoogle Scholar
  42. 42.
    Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks SK, Kasahara T (2000) Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem 275:16309–16315CrossRefPubMedGoogle Scholar
  43. 43.
    Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111:278–285CrossRefPubMedGoogle Scholar
  44. 44.
    Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, Howley PM (1996) Inhibition of cyclin D-CDK4/CDK 6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A 93:424–429CrossRefGoogle Scholar
  45. 45.
    Tong X, Howley PM (1997) The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proc Natl Acad Sci U S A 94:4412–4417CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Shintani S, Mihara M, Nakahara Y, Kiyota A, Yoshihama Y, Ueyama Y, Matsumura T (2000) Infrequent alternations of RB pathway(Rb-p16INK4A-cyclinD1) in adenoid cystic carcinoma of salivary glands. Anticancer Res 20:2169–2175PubMedGoogle Scholar
  47. 47.
    Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M, Kitajima M (1997) Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 3:2229–2236PubMedGoogle Scholar
  48. 48.
    Namazie A, Alavi S, Olopade OI, Pauletti G, Aghamohammadi N, Aghamohammadi M, Gornbein JA, Calcaterra TC, Slamon DJ, Wang MB, Srivatsan ES (2002) Cyclin D1 amplification and p16(MTS1/CDK4I)deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 112:472–481CrossRefPubMedGoogle Scholar
  49. 49.
    Zafereo ME, Xu L, Dahlstrom KR, Viamonte CA, El-Naggar AK, Wei Q, Li G, Sturgis EM (2016) Squamous cell carcinoma of the oral cavity often overexpresses p16 but is rarely driven by human papillomavirus. Oral Oncol 56:47–53CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Kouketsu A, Sato I, Abe S, Oikawa M, Shimizu Y, Takahashi T, Kumamoto H (2016) Detection of human papillomavirus infection in oral squamous cell carcinoma: a cohort study of Japanese patients. J Oral Pathol Med 45:565–572CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Götz C, Drecoll E, Straub M, Bissinger O, Wolff KD, Kolk A (2016) Impact of HPV infection on oral squamous cell carcinoma. Oncotarget 7:76704–76712CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Ohara T, Kawashiri S, Tanaka A, Noguchi N, Kitahara H, Okamune A, Kato K, Hase T, Nakaya H, Yoshizawa K (2009) Integrin expression levels correlate with invasion, metastasis and prognosis of oral squamous cell carcinoma. Pathol Oncol Res 15:429–436CrossRefPubMedGoogle Scholar
  53. 53.
    Raguse JD, Gath HJ, Bier J, Riess H, Oettle H (2004) Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol 40:228–230CrossRefPubMedGoogle Scholar
  54. 54.
    Brown NF, Williams M, Arkenau HT, Fleming RA, Tolson J, Yan L, Zhang J, Swartz L, Singh R, Auger KR, Lenox L, Cox D, Lewis Y, Plisson C, Searle G, Saleem A, Blagden S, Mulholland P (2018) A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098. Neuro-Oncology 20:1634–1642CrossRefPubMedGoogle Scholar
  55. 55.
    Jeong K, Murphy JM, Rodriguez YAR, Kim JS, Ahn EE, Lim SS (2019) FAK inhibition reduces metastasis of α4 integrin-expressing melanoma to lymph nodes by targeting lymphatic VCAM-1 expression. Biochem Biophys Res Commun 509:1034–1040CrossRefPubMedGoogle Scholar
  56. 56.
    Hu C, Chen X, Wen J, Gong L, Liu Z, Wang J, Liang J, Hu F, Zhou Q, Wei L, Shen Y, Zhang W (2017) Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo. Cancer Sci 108:1347–1356CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Shimizu T, Fukuoka K, Takeda M, Iwasa T, Yoshida T, Horobin J, Keegan M, Vaickus L, Chavan A, Padval M, Nakagawa K (2016) A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 77:997–1003CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Kurio N, Shimo T, Fukazawa T, Okui T, Hassan NM, Honami T, Horikiri Y, Hatakeyama S, Takaoka M, Naomoto Y, Sasaki A (2012) Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma. Oral Oncol 48:1159–1170CrossRefPubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2019

Authors and Affiliations

  1. 1.Department of Oral and Maxillofacial SurgeryKanazawa University Graduate School of Medical ScienceKanazawaJapan

Personalised recommendations